XBiotech/$XBIT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About XBiotech
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Ticker
$XBIT
Sector
Primary listing
Employees
85
Headquarters
Website
XBiotech Metrics
BasicAdvanced
$79m
-
-$1.49
0.89
-
Price and volume
Market cap
$79m
Beta
0.89
52-week high
$3.61
52-week low
$2.09
Average daily volume
41k
Financial strength
Current ratio
16.011
Quick ratio
15.88
Interest coverage (TTM)
-632.78%
Profitability
EBITDA (TTM)
-53.999
Effective tax rate (TTM)
-0.52%
Management effectiveness
Return on assets (TTM)
-19.93%
Return on equity (TTM)
-28.23%
Valuation
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-1.952
Free cash flow yield (TTM)
-51.22%
Free cash flow per share (TTM)
-1.319
Growth
Earnings per share change (TTM)
18.09%
3-year earnings per share growth (CAGR)
11.39%
10-year earnings per share growth (CAGR)
2.07%
XBiotech Financial Performance
Revenues and expenses
XBiotech Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for XBiotech stock?
XBiotech (XBIT) has a market cap of $79M as of April 28, 2026.
What is the P/E ratio for XBiotech stock?
The price to earnings (P/E) ratio for XBiotech (XBIT) stock is 0 as of April 28, 2026.
Does XBiotech stock pay dividends?
No, XBiotech (XBIT) stock does not pay dividends to its shareholders as of April 28, 2026.
When is the next XBiotech dividend payment date?
XBiotech (XBIT) stock does not pay dividends to its shareholders.
What is the beta indicator for XBiotech?
XBiotech (XBIT) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.